Contrast-associated acute kidney injury (CA-AKI) remains one of the most relevant procedural complications in patients undergoing transcatheter aortic valve implantation (TAVI). Beyond contrast dye administration, CA-AKI following TAVI is facilitated by temporary hypoperfusion due to rapid pacing, concomitant medications (e.g. general anesthesia) and pre-existing comorbidities. Its occurrence has been consistently associated with adverse short- and long-term outcomes, including increased mortality, prolonged hospitalization and greater need for supportive care [1–3].
